Palisade Bio adds IBD expert to clinical advisory board

Palisade Bio, Inc. (NASDAQ: PALI) announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board as the company prepares to advance its drug candidate PALI-2108 into Phase 2 development for ulcerative colitis and fibrostenotic Crohn's disease.

Dr. Verstockt serves as an IBD staff physician and professor in the Department of Gastroenterology and Hepatology at University Hospitals Leuven and KU Leuven in Belgium. His research focuses on precision medicine in inflammatory bowel disease, biomarker development, and non-invasive disease monitoring techniques.

The company plans to submit an Investigational New Drug application for a Phase 2 study of PALI-2108 in ulcerative colitis in the first half of 2026, with parallel development planning underway for fibrostenotic Crohn's disease.

PALI-2108 is a once-daily oral prodrug designed for targeted delivery of PDE4 inhibition to the terminal ileum and colon. The drug remains inactive until bacterial enzymes in the lower intestine convert it into an active PDE4 inhibitor at sites of inflammation and fibrosis.

In a Phase 1b trial, PALI-2108 achieved clinical response in the ulcerative colitis cohort, with no serious adverse events reported. The company stated the results showed favorable tolerability and pharmacokinetics consistent with localized activation in the lower intestine.

Palisade Bio is a clinical-stage biopharmaceutical company based in Carlsbad, California, developing oral PDE4 inhibitor prodrugs for inflammatory and fibrotic diseases.

You May Also Be Interested In

• TRWD adds programmer Jeremy Woertink to its advisory board
• Elutia agrees to sell SimpliDerm unit for up to $11 million
• Harmony Biosciences posts record Q2 revenue, CFO steps down